Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Merck (MRK) PT Lowered to $69 at Leerink Partners

October 30, 2017 7:49 AM EDT

Leerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results

Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.

... More